| Literature DB >> 30307034 |
Alina Johansson1, William A Nyberg1, Maria Sjöstrand1, Noah Moruzzi2, Petra Bergman3, Mohsen Khademi3, Magnus Andersson3,4, Fredrik Piehl3,4, Per-Olof Berggren2, Ruxandra Covacu3, Maja Jagodic3, Alexander Espinosa1.
Abstract
Systemic autoimmune diseases are characterized by the overexpression of type I IFN stimulated genes, and accumulating evidence indicate a role for type I IFNs in these diseases. However, the underlying mechanisms for this are still poorly understood. To explore the role of type I IFN regulated miRNAs in systemic autoimmune disease, we characterized cellular expression of miRNAs during both acute and chronic type I IFN responses. We identified a T cell-specific reduction of miR-31-5p levels, both after intramuscular injection of IFNβ and in patients with Sjögren's syndrome (SjS). To interrogate the role of miR-31-51p in T cells we transfected human CD4+ T cells with a miR-31-5p inhibitor and performed metabolic measurements. This identified an increase in basal levels of glucose metabolism after inhibition of miR-31-5p. Furthermore, treatment with IFN-α also increased the basal levels of human CD4+ T-cell metabolism. In all, our results suggest that reduced levels of miR-31-5p in T cells of SjS patients support autoimmune T-cell responses during chronic type I IFN exposure.Entities:
Keywords: Autoimmunity; Immune regulation; Interferons; Metabolism; Rheumatology
Year: 2018 PMID: 30307034 DOI: 10.1002/eji.201747416
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532